A phase Ib trial of subcutaneous, outpatient interleukin-2 [aldesleukin] for patients with stage III or IV mycosis fungoides
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary)
- Indications Mycosis fungoides
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2012 Biomarkers information updated
- 18 Dec 2007 New trial record.